Company Overview
Rhythm Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to developing treatments for rare neuroendocrine diseases within the United States and international markets. The company focuses its research and development efforts on IMCIVREE (setmelanotide), which serves as a lead product candidate targeting the rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin-related disorders. This business model places Rhythm within the Healthcare sector, specifically the Biotechnology industry, where high-risk research and development phases are standard before commercial viability is achieved. With a market capitalization of $6.17B, annual revenue of $189.76M, and an employee base of 414, the company has established a significant presence in a niche therapeutic area. These valuation and revenue figures indicate that the market assigns substantial value to the company's pipeline and its potential to capture a share of the rare disease market, positioning it as a major player despite its current stage of commercialization.
Financial Health
The company reported revenue of $189.76M for the trailing twelve months, while net income stood at -$201,916,992 and EBITDA was -$190,678,000. The substantial gap between the positive revenue of $189.76M and the negative net income of -$201.92M reveals a cost structure where expenses significantly exceed top-line earnings, a common characteristic in the early commercial stages of biotechnology. Free cash flow is reported at -$145,983,376, which indicates that the company is currently burning cash to fund operations and growth initiatives rather than generating liquidity for shareholders. This negative free cash flow suggests limited immediate financial flexibility, requiring the company to rely on existing cash reserves or external financing to sustain its activities. The gross margin stands at 89.7%, indicating high efficiency in production relative to the cost of goods sold, yet the operating margin is -82.2% and the profit margin is -103.6%, highlighting massive overhead costs relative to sales. Total cash on hand is $388.95M compared to total debt of $112.17M, resulting in a debt-to-equity ratio of 41.54, which suggests the company maintains a conservative balance sheet regarding leverage despite the high debt-to-equity figure reflecting equity shrinkage due to losses. The current ratio is 4.41, indicating strong short-term liquidity as current assets are more than four times current liabilities. Return on Equity is -90.5% and Return on Assets is -27.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of generating profit due to the pre-revenue or low-revenue nature of the business.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the negative net income, while the Forward P/E is -238.59, implying that future earnings expectations have not yet turned positive to support a traditional valuation multiple. The price-to-book ratio is 43.65, which indicates a significant market premium over the company's book value, reflecting investor confidence in the potential value of the company's intellectual property and pipeline assets rather than its current book equity. The price-to-sales ratio is 32.50 and the EV/EBITDA is -31.58, suggesting that the market is valuing the company primarily on its sales potential and revenue growth trajectory rather than current profitability or earnings power. The stock has a 52-week high of $122.20 and a 52-week low of $45.91, providing a historical range within which the current price must be situated to understand recent market sentiment and volatility. The beta value is 2.15, which means the stock price is expected to be approximately twice as volatile as the broader market, exposing investors to higher fluctuations in share price during periods of market instability.
Growth & Income
Revenue growth year-over-year is 36.9%, while earnings growth is N/A because the company has not yet achieved profitability. Since earnings growth is not calculable in the traditional sense due to negative earnings, the revenue expansion of 36.9% serves as the primary indicator of business scale-up and market penetration. The company does not pay dividends, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all generated cash is reinvested into research, development, and commercial expansion rather than distributed to shareholders. This reinvestment strategy is typical for biotechnology firms that prioritize scaling their product portfolios over returning capital to investors. The overall growth and income profile is characterized by rapid revenue expansion funded by existing cash reserves, with no current income distribution to compensate for the lack of earnings.